As AbbVie prepares to lose market exclusivity for its leading drug, Humira, the company projects robust sales exceeding $15 billion from its newer offerings, Skyrizi and Rinvoq, by 2025. Despite recently experiencing declines in Humira sales due to biosimilars, AbbVie has seen its shares rise 13% this year, signaling strong investor confidence. The stock is considered an outstanding buy at a forward P/E ratio of 10.87, which is favorable compared to industry standards. In addition, AbbVie is proactively pursuing innovation, applying for FDA approval for a new advanced Parkinson's disease drug.
“AbbVie · expects combined sales of · Skyrizi and Rinvoq · more than $15 billion by 2025”
“AbbVie · shares are up by · S&P 500 index · 13%”
“Humira · is the top-selling drug for · AbbVie”
“AbbVie · is · an outstanding stock to buy · true”
“AbbVie · has · outperformed the market · easily”
“AbbVie · is · reasonably valued · true”
“Shares of AbbVie · are up · about 13% · this year”
“top-selling drug for AbbVie · is · Humira”
“AbbVie (ABBV) · closed at · $153.14 · +0.53% move from the prior day”
“AbbVie (ABBV) · outpaced · S&P 500's daily loss · 0.3%”
“AbbVie (ABBV) · gained · 1.56% · in the past month”
“AbbVie (ABBV) · expected to report EPS of · $3.43 · up 10.29% from the prior-year quarter”
